Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2014 | Selected Commenatary | Ausgabe 3/2014

European Surgery 3/2014

Selected commentary to “Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia. A randomized clinical trial”

European Surgery > Ausgabe 3/2014
M. Riegler, Univ.-Prof. Dr. S. F. Schoppmann
Wichtige Hinweise
Phoa K, van Vilsteren FI, Weusten BM, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209–17.



Barrett’s esophagus (BE) results from gastroesophageal reflux disease (GERD) and harbors an increased cancer risk. Via low (LGD) and high grade dysplasia (HGD) BE may progress towards cancer (0.5 %–0.75 % annual risk). Radiofrequency ablation (RFA) represents a novel endoscopic method for durable elimination of BE. RFA is effective for cancer prevention persons with HGD. Remains to be questioned the value of RFA in those with LGD.


Critical analysis of the paper by Phoa K et al., published in the recent issue of JAMA. The randomized clinical study compared the effect of surveillance vs. RFA in persons with BE and LGD.


After 3 years, RFA was superior vs. surveillance as it significantly inhibited progression to cancer and/or high grade dysplasia (1.5 % vs. 26.5 %). The number necessary to treat to prevent cancer/HGD and cancer was 4.0 and 13.6, respectively.


RFA is superior to surveillance to prevent the progression of BE with LGD to HGD/cancer and cancer. Thus RFA should be recommended as the treatment of choice for the management of BE with LGD in those fit for the endoscopic procedure. Future studies will have to elicit the impact of orchestrated therapy of dysplastic BE including anti reflux surgery. Finally the value of RFA for cancer development in those with non-dysplastic BE should be addressed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3/2014

European Surgery 3/2014 Zur Ausgabe